Letter: Aricept: waiting for the data
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Sir: Your article "The truth about Aricept - a new drug for Alzheimer's" (5 August) is seriously premature in taking so restricted a view of this drug's potential. "The truth" will not be known until we have more experience.
Aricept is currently used only on patients in the comparatively early stages of Alzheimer's disease. The drug's trial data was based on that patient group, so that is the group for which it is licensed.
That does not necessarily mean - as stated in your article - that it has no effect on more serious cases; nor that "Aricept works only for Alzheimer's; it is not effective for other forms of dementia". There simply isn't any research data available: we don't know the answer either way. It is far too early to rule out categorically further uses for this important development in Alzheimer's treatment.
Your point about funding fears and the patchy availability of the drug across the UK is well made. In Southampton, as in other areas, the use of memory clinics will identify patients likely to benefit from the new therapy and - crucially - monitor their progress over a period of months to ensure that this expensive treatment is concentrated on patients who experience a clear benefit.
We expect patients to stay on Aricept for less time (on average) than was initially predicted on its launch - so the real costs of making it available will be far lower than initially feared. Conclusive evidence that this is the case should reassure reluctant prescribers - and ultimately ensure that this and similar future drug therapies become more widely and evenly available nationwide.
Dr DAVID WILKINSON
Director, Thornhill Research Unit
Southampton Community Health Services NHS Trust
Southampton
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments